HP Free cash flow decreased by 89.5% to $150.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 108.3%, from $72.00M to $150.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -16.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.33B | $935.00M | $2.68B | $1.38B | $330.00M | $198.00M | $1.79B | -$208.00M | $506.00M | $839.00M | $1.84B | -$37.00M | $462.00M | $1.26B | $1.47B | $72.00M | -$145.00M | $1.45B | $1.43B | $150.00M |
| QoQ Change | — | -29.4% | +186.2% | -48.3% | -76.2% | -40.0% | +802.0% | -111.6% | +343.3% | +65.8% | +119.4% | -102.0% | >999% | +173.2% | +16.5% | -95.1% | -301.4% | >999% | -1.3% | -89.5% |
| YoY Change | — | — | — | — | -75.1% | -78.8% | -33.3% | -115.0% | +53.3% | +323.7% | +3.1% | +82.2% | -8.7% | +50.4% | -20.2% | +294.6% | -131.4% | +14.6% | -2.9% | +108.3% |